Growth HormoneModerate Evidence

Ipamorelin

Also known as: NNC 26-0161

Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.

Evidence

Moderate

FDA status

Not FDA-approved

Source

Synthetic ghrelin mimetic pentapeptide

Overview

Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.

Mechanism of Action

Binds ghrelin receptor (GHS-R1a) on pituitary cells, triggers rapid GH release without hypothalamic involvement, no cortisol or prolactin elevation, studied alongside GHRH analogs.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Rapid GH pulse induction
  • No cortisol or prolactin spike
  • Improved body composition
  • Enhanced recovery
  • Better sleep
  • Combination with GHRH analogs (research)

Researched for

Research topics, not approved uses.

Growth hormone deficiencyAge-related GH declineAthletic recoveryBody composition goalsSleep quality improvement

How Gabriel approaches peptides

Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Ipamorelin isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Moderate
Studies

Clinical trials, safety studies in adults

Summary

Human studies show it raises GH. It was tested for bowel recovery after surgery and development stopped. FDA lists it among bulk substances that may present significant safety risks in compounding.

Safety Information

Potential Side Effects

  • •Increased hunger
  • •Water retention (mild)
  • •Headache

Contraindications

  • Active cancer
  • Pregnancy
  • Breastfeeding

Interactions

  • ⚠Synergistic with GHRH analogs

Quick Facts

CategoryGrowth Hormone
SourceSynthetic ghrelin mimetic pentapeptide
StatusNot FDA-approved; FDA lists it among substances that may present significant safety risks in compounding